The impact of glucocorticoids on the efficacy of JAK inhibitors or non-TNF-targeted biologics in RA
JAKi did not show superiority over OMA regarding steroid-sparing effects; however, JAKi yielded higher remission rates. Exposure to GC at 6 months predicted poorer 24-month outcomes.
Authors
- Francesca Frizzera (ORCID: https://orcid.org/0000-0002-0611-5605)
- F. Arru
- Mariangela Salvato (ORCID: https://orcid.org/0009-0005-5809-6716)
- Alessandro Giollo (ORCID: https://orcid.org/0000-0001-9355-7673)
- Andrea Doria (ORCID: https://orcid.org/0000-0003-0548-4983)
- Benedetta Salvatori (ORCID: https://orcid.org/0000-0002-4878-8699)
- Margherita Zen (ORCID: https://orcid.org/0000-0003-0835-1406)
- Lorenzo Di Luozzo
- Kiren Khalid
Institutions
- University of Padua (IT)
- Istituto Giannina Gaslini (IT)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2025-11-14
- DOI
- https://doi.org/10.1093/rheumatology/keaf612
- Primary Topic
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00